Sugi Predict

Sugi Predict / Compounds / SCHEMBL616699

SCHEMBL616699

SCHEMBL616699

Cc1nc2cc(Br)ccn2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 5/20 0.57
▸ HAVCR2 Q8TDQ0 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.34
▸ HTT P42858 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ TP53 P04637 2/20 0.33
▸ PDE10A Q9Y233 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ NPC1 O15118 3/20 0.33
▸ RAB9A P51151 3/20 0.33
▸ HCRTR1 O43613 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ PIK3CD O00329 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ PIK3CG P48736 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7920632 0.80 KDM4E (0.42) AHRKDM4EHTTALDH1A1MAPK1
SCHEMBL9104806 0.80 AHR (0.61) AHRPIK3CDPIK3CAPIK3CG
SCHEMBL31489689 0.78 AHR (0.50) AHRKDM4EHTTALDH1A1MAPK1
SCHEMBL16979292 0.77 KDM4E (0.40) AHRHAVCR2KDM4EHTTALDH1A1
SCHEMBL31257450 0.77 AHR (0.34) AHRKDM4EHTTALDH1A1MAPK1
SCHEMBL24348565 0.77 AHR (0.34) AHRKDM4EHTTALDH1A1MAPK1
SCHEMBL14007016 0.77 PIK3CG (0.38) AHRKDM4EHTTALDH1A1MAPK1
SCHEMBL27038051 0.77 AHR (0.57) AHRHTT
SCHEMBL31096177 0.77 AHR (0.57) AHRHTTALDH1A1MAPTNPC1
SCHEMBL42128 0.77 AHR (0.57) AHRPIK3CDPIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4105216-B1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-05-20 — — EP disclosed
US-20260070902-A1 SULFONYL DERIVATIVES AS CCR6 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-03-12 — — US disclosed
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 — — US disclosed
EP-4661964-A1 COMPOUNDS AS CCR6 INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-12-17 — — EP disclosed
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-11-20 — — US disclosed
EP-4630402-A1 SULFONYL DERIVATIVES AS CCR6 INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-10-15 — — EP disclosed
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 — — US disclosed
WO-2025137640-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-26 — — WO disclosed
WO-2025111547-A1 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF RGENTA THERAPEUTICS, INC. (US) 2025-05-30 — — WO disclosed
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 — — US disclosed
US-8575337-B2 Oxazolidinone derivative having fused ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-11-05 — — US disclosed
US-8575337-B2 Oxazolidinone derivative having fused ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-11-05 — — US disclosed
US-8575337-B2 Oxazolidinone derivative having fused ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-11-05 — — US disclosed
EP-2393813-B1 Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol VITAE PHARMACEUTICALS INC (US) 2013-07-31 — — EP disclosed
US-20120040973-A1 DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS VITAE PHARMACEUTICALS, INC. (US) 2012-02-16 — — US disclosed
EP-2393813-A2 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 Vitae Pharmaceuticals, Inc. (US) 2011-12-14 — — EP disclosed
US-20110098471-A1 OXAZOLIDINONE DERIVATIVE HAVING FUSED RING RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-04-28 — — US disclosed
US-20110098471-A1 OXAZOLIDINONE DERIVATIVE HAVING FUSED RING RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-04-28 — — US disclosed
US-20110098471-A1 OXAZOLIDINONE DERIVATIVE HAVING FUSED RING RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-04-28 — — US disclosed
WO-2010091067-A2 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 VITAE PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM AHR 4360/4885HAVCR2 3039/4885KDM4E 3650/4885
US-20110098471-A1 OXAZOLIDINONE DERIVATIVE HAVING FUSED RING OXER1, ALOX12, CYP1A1 AHR 20/4885HAVCR2 389/4885KDM4E 3827/4885
US-20260070902-A1 SULFONYL DERIVATIVES AS CCR6 INHIBITORS CCR6, CCR1, CCR4 AHR 271/4885HAVCR2 129/4885KDM4E 2904/4885
US-20120040973-A1 DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS HSD11B1, HSD11B2, HSD17B1 AHR 3002/4885HAVCR2 2765/4885KDM4E 3015/4885
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 AHR 4557/4885HAVCR2 1194/4885KDM4E 3046/4885
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS CCR6, CCR4, CCR1 AHR 576/4885HAVCR2 606/4885KDM4E 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.